A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer

Abstract only

Saved in:

Bibliographic Details
Published in	Journal of clinical oncology Vol. 34; no. 15_suppl; p. TPS5608
Main Authors	Herzog, Thomas J., Ghamande, Sharad A., Gabra, Hani, Armstrong, Deborah Kay, Fujiwara, Keiichi, Monk, Bradley J., Pignata, Sandro, Gonzalez-Martin, Antonio, Sehouli, Jalid, Schweizer, Charles, Weil, Susan, Hoffman, Kimberly, Grasso, Luigi, Coleman, Robert L., Vergote, Ignace
Format	Journal Article
Language	English
Published	20.05.2016
Online Access	Get full text

Loading…